<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-143426" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Small Fiber Neuropathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cascio</surname>
            <given-names>Matthew A.</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mukhdomi</surname>
            <given-names>Taif</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Matthew Cascio declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Taif Mukhdomi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>12</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-143426.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Small fiber neuropathy presents with burning pain, often beginning in the extremities, most notably in the feet. It is due to the involvement of A-delta and C nerve fibers. It may occur idiopathically or due to metabolic, hereditary, infectious, immune-mediated, or toxic etiologies. It must be promptly diagnosed and treated to avoid pain, debility, or possible large nerve fiber involvement. This activity reviews the evaluation and treatment of small fiber neuropathy and highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the different etiologies of small fiber neuropathy.</p></list-item><list-item><p>Assess&#x000a0;the proper evaluation of small fiber neuropathy, including patient history and examination findings.</p></list-item><list-item><p>Evaluate&#x000a0;the management options available for small fiber neuropathy.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies to improve outcomes in small fiber neuropathy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=143426&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=143426">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-143426.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Peripheral neuropathy is a prevalent&#x000a0;problem, affecting an estimated 15 to 20 million people in the United States above the age of 40.<xref ref-type="bibr" rid="article-143426.r1">[1]</xref>&#x000a0;It is the most common cause&#x000a0;of outpatient neurology appointments&#x000a0;in the United States and accounts for healthcare spending over $10 billion annually.<xref ref-type="bibr" rid="article-143426.r2">[2]</xref>&#x000a0;In many affected individuals, such neuropathies involve the small nerve fibers, including the&#x000a0;peripheral thinly myelinated&#x000a0;A&#x003b4; fibers and&#x000a0;unmyelinated C nerve fibers.<xref ref-type="bibr" rid="article-143426.r3">[3]</xref>&#x000a0;Involvement of these small nerve fibers, referred to as small fiber neuropathy (SFN), typically presents with pain, burning, numbness, and tingling, often in a&#x000a0;stocking-glove distribution, with symptoms typically starting in the feet and ascending superiorly.</p>
      </sec>
      <sec id="article-143426.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>SFN&#x000a0;affects the small myelinated&#x000a0;A<italic toggle="yes">&#x003b4;</italic>-fibers and the unmyelinated C-fibers.<xref ref-type="bibr" rid="article-143426.r4">[4]</xref>&#x000a0;SFN may affect sensory and autonomic fibers, leading to sensory changes, autonomic dysfunction, or a combination of symptoms.<xref ref-type="bibr" rid="article-143426.r5">[5]</xref>&#x000a0;The autonomic small nerve fibers transmit thermoregulatory, cardiovascular, gastrointestinal, sudomotor, urogenital, and other autonomic signals, while the somatic small nerve fibers transmit pain, temperature, and itch information.<xref ref-type="bibr" rid="article-143426.r6">[6]</xref>&#x000a0;General symptoms of SFN include fatigue, cognitive disturbances, headache, and widespread musculoskeletal pain, which may negatively impact their quality of life. SFN is associated with many diseases but may also present idiopathic.&#x000a0;The etiologies of SFN can be broken down into&#x000a0;6 categories.<xref ref-type="bibr" rid="article-143426.r7">[7]</xref></p>
        <p>
<bold>Hereditary</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Fabry's disease</p>
          </list-item>
          <list-item>
            <p>Mutation in sodium channels</p>
          </list-item>
          <list-item>
            <p>Wilsons disease</p>
          </list-item>
          <list-item>
            <p>Familial amyloidosis</p>
          </list-item>
        </list>
        <p>
<bold>Infectious</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>HIV</p>
          </list-item>
          <list-item>
            <p>Lyme</p>
          </list-item>
          <list-item>
            <p>Hepatitis C</p>
          </list-item>
        </list>
        <p>
<bold>Toxic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Alcohol</p>
          </list-item>
          <list-item>
            <p>Chemotherapy</p>
          </list-item>
          <list-item>
            <p>Neurotoxic drugs</p>
          </list-item>
          <list-item>
            <p>Vaccine-associated</p>
          </list-item>
        </list>
        <p>
<bold>Immune-Mediated</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ehlers- Danlos</p>
          </list-item>
          <list-item>
            <p>Fibromyalgia</p>
          </list-item>
          <list-item>
            <p>Monoclonal gammopathy</p>
          </list-item>
          <list-item>
            <p>Acute inflammatory&#x000a0;SFN</p>
          </list-item>
          <list-item>
            <p>Lupus</p>
          </list-item>
          <list-item>
            <p>Connective tissue disease</p>
          </list-item>
          <list-item>
            <p>Chronic inflammatory demyelinating polyneuropathy</p>
          </list-item>
          <list-item>
            <p>Sarcoidosis</p>
          </list-item>
          <list-item>
            <p>Rheumatic diseases (undifferentiated connective tissue disorders, rheumatoid arthritis, psoriatic arthropathy)</p>
          </list-item>
          <list-item>
            <p>Sj&#x000f6;gren syndrome, Primary systemic amyloidosis</p>
          </list-item>
        </list>
        <p>
<bold>Metabolic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diabetes mellitus</p>
          </list-item>
          <list-item>
            <p>Impaired glucose tolerance</p>
          </list-item>
          <list-item>
            <p>Vitamin B12 deficiency</p>
          </list-item>
          <list-item>
            <p>Copper deficiency</p>
          </list-item>
          <list-item>
            <p>Abnormal thyroid function</p>
          </list-item>
        </list>
        <p>
<bold>Idiopathic</bold>
</p>
      </sec>
      <sec id="article-143426.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>A cross-sectional epidemiological retrospective study of SFN conducted in the Netherlands found an incidence of 12 cases per 100,000/year, with a prevalence of 53 cases per 100,000.&#x000a0;This study found SFN to be more commonly seen in men and more frequently diagnosed in patients over 65. These disease rates are likely underestimated due to a lack of awareness and a lack of standardized&#x000a0;diagnostic criteria, with rates expected to increase in the coming years with increased awareness of SFN.<xref ref-type="bibr" rid="article-143426.r8">[8]</xref></p>
      </sec>
      <sec id="article-143426.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The nerves of the peripheral nervous system are classified into different types based on a multitude of factors, including diameter, myelination, and conduction velocity, see Table 1. A<italic toggle="yes">&#x003b1;</italic>- and A&#x003b2;-fibers are considered&#x000a0;large nerve fibers, while&#x000a0;A<italic toggle="yes">&#x003b4;</italic>- and C-fibers are considered&#x000a0;small nerve fibers. Amongst small fibers, myelinated&#x000a0;A<italic toggle="yes">&#x003b4;</italic>-fibers demonstrate faster conduction velocities (4&#x000a0;to 36 m/s)&#x000a0;than unmyelinated C-fibers (0.4&#x000a0;to 2.8 m/s).<xref ref-type="bibr" rid="article-143426.r9">[9]</xref>&#x000a0;This difference is due to the larger diameter and presence of myelin.<xref ref-type="bibr" rid="article-143426.r10">[10]</xref>&#x000a0;SFN is defined as a dysfunction of these small&#x000a0;A<italic toggle="yes">&#x003b4;&#x000a0;</italic>and C fibers, which occurs by an unclear mechanism. Demyelinating processes are unlikely to be the underlying pathogenesis as demyelinating processes do not solely affect small fibers. Thus, distal axonal loss or neuronal degeneration is believed to be the most likely underlying etiology for SFN.<xref ref-type="bibr" rid="article-143426.r5">[5]</xref>&#x000a0;</p>
        <table-wrap id="article-143426.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1.</title>
          </caption>
          <table border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Fiber Type</td>
                <td rowspan="1" colspan="1">Diameter</td>
                <td rowspan="1" colspan="1">Velocity</td>
                <td rowspan="1" colspan="1">Characteristics</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">A<italic toggle="yes">&#x003b1;</italic>- and A&#x003b2;-fibers</td>
                <td rowspan="1" colspan="1">
<p>A<italic toggle="yes">&#x003b1;:&#x000a0;</italic>12-20&#x000a0;&#x003bc;m</p>
<p>A&#x003b2;: 6-12&#x000a0;&#x003bc;m</p>
</td>
                <td rowspan="1" colspan="1">
<p>A<italic toggle="yes">&#x003b1;:&#x000a0;</italic>72-120 m/s</p>
<p>A&#x003b2;: 36-72 m/s</p>
</td>
                <td rowspan="1" colspan="1">
<p>Large Fiber</p>
<p>Myelinated</p>
<p>Proprioception, light touch</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">A<italic toggle="yes">&#x003b4;&#x000a0;</italic>fibers</td>
                <td rowspan="1" colspan="1">1-6&#x000a0;&#x003bc;m</td>
                <td rowspan="1" colspan="1">4-36 m/s</td>
                <td rowspan="1" colspan="1">
<p>Medium fiber</p>
<p>Lightly myelinated</p>
<p>Nocioception (mechanical, chemical, thermal)</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">C fibers</td>
                <td rowspan="1" colspan="1">0.2-1.5&#x000a0;&#x003bc;m</td>
                <td rowspan="1" colspan="1">0.4-2.8&#x000a0;m/s</td>
                <td rowspan="1" colspan="1">
<p>Small fiber</p>
<p>Unmyelinated</p>
<p>Temperature, itch, Nocioception (mechanical, chemical, thermal)</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-143426.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A thorough history and physical exam are crucial in the evaluation of SFN. Patients with SFN often present initially with sensory symptoms, including pain, burning, numbness, and tingling. While most cases of SFN present in a&#x000a0;length-dependent pattern&#x000a0;(symptoms beginning in the feet and advancing proximally), some cases have followed either a non-length-dependent (proximal, diffuse, or patchy distribution involving different body parts including the mouth, face, trunk, scalp, or upper limbs before or simultaneously with lower limb involvement)&#x000a0;or an&#x000a0;asymmetric mono/multiplex neuropathy (involvement of&#x000a0;1 or more sensory peripheral nerve, often with burning mouth syndrome, vulvodynia, or notalgia and meralgia parasthetica).<xref ref-type="bibr" rid="article-143426.r3">[3]</xref>&#x000a0;Length-dependent SFN often occurs due to metabolic causes, including diabetes or neurotoxic exposure. In contrast, non-length-dependent SFN often occurs due to paraneoplastic disorders and immune-mediated pathologies such as Sj&#x000f6;gren syndrome.<xref ref-type="bibr" rid="article-143426.r11">[11]</xref>&#x000a0;</p>
        <p>Patients with SFN often present initially with neuropathic foot pain. Symptoms may be mild at onset, with some patients noting a vague foot discomfort. Reported descriptions may include numbness in the toes, a wooden quality in the feet, or a feeling the patient&#x000a0;describes as&#x000a0;walking on sand, golf balls, or pebbles. Burning pain in the feet, expanding proximally in a stocking-glove distribution, is often the most bothersome and typical symptom. This burning is often accompanied by aching or stabbing pains, pins and needles sensation, electric shock, or cramping in the feet and calves.&#x000a0;Patients with SFN typically experience the worst of their symptoms at night, often complaining of restless legs, bed sheet intolerance, and clothes causing allodynia or dysesthesia.&#x000a0;Some patients do not report pain but note swelling and tightness in their feet. Autonomic fiber involvement may lead to additional symptoms, including dry mouth, dry eyes, constipation, bladder incontinence, orthostatic dizziness, sexual dysfunction, red or white skin discoloration, or trouble sweating.&#x000a0;</p>
        <p>Upon&#x000a0;initial presentation, a&#x000a0;detailed history should be obtained, including medical history, family history, alcohol use, and use of neurotoxic medications such as&#x000a0;colchicine, metronidazole, and chemotherapeutics.<xref ref-type="bibr" rid="article-143426.r2">[2]</xref>&#x000a0;Given the known association between SFN and conditions such as hepatitis C and Human immunodeficiency virus (HIV), the examiner should inquire about relevant risk factors such as sexual history, intravenous drug use, and blood transfusions.&#x000a0;A thorough neurologic physical exam can differentiate small fiber from large fiber neuropathy. Examination often demonstrates allodynia, hyperalgesia, or reduced thermal and pinprick sensation in the affected area. Findings such as weakness, reduced proprioception, and&#x000a0;absent deep tendon reflexes should not be seen in SFN, as they indicate large fiber involvement. When history is suspicious for autonomic fiber involvement, vitals should be checked to screen for orthostatic hypotension, and skin should be checked, which may appear dry, shiny, atrophic, discolored, or mildly edematous due to vasomotor or sudomotor abnormalities. A physical exam should also evaluate any previously mentioned systemic disorders associated with SFN.</p>
      </sec>
      <sec id="article-143426.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnostic evaluation for suspected SFN often involves a multitude of tests. While nerve conduction studies and needle EMG demonstrate only large fiber involvement leading to normal results in patients with isolated small fiber involvement, these tests may be useful in evaluating subclinical large nerve fiber involvement and alternative diagnoses, including alternative diagnoses lumbosacral radiculopathy.&#x000a0;Small fibers travel too slowly, and their conduction responses cannot be captured by a nerve conduction study, a routine test performed to evaluate large sensory and motor nerve fibers. Therefore, a skin biopsy is often used to assess small sensory nerve fibers in the skin.&#x000a0;Skin biopsy is a minimally invasive procedure that may also be used to evaluate intraepidermal nerve fiber density. Skin specimens are typically obtained by a 3 mm punch biopsy at the distal leg and thigh and are then sent for laboratory analysis. SFN may be diagnosed if the intraepidermal nerve fiber density is less than normal. Skin biopsy testing has an 88% sensitivity in the diagnosis of SFN.<xref ref-type="bibr" rid="article-143426.r12">[12]</xref>&#x000a0;An additional test may be performed is quantitative sudomotor axon reflex testing (QSART), a noninvasive autonomic study used to assess the volume of sweat produced in the limbs in response to acetylcholine. QSART can measure postganglionic sympathetic sudomotor nerve function and may provide a sensitivity of up to 80% in the diagnosis of SFN.<xref ref-type="bibr" rid="article-143426.r13">[13]</xref>&#x000a0;</p>
        <p>Additional useful diagnostic tests may include tilt-table and cardiovagal testing for patients with palpitations and orthostasis and thermoregulatory sweat testing for patients with abnormal sweating patterns. The diagnosis of SFN remains difficult as there is not yet an available gold standard test. While some sources have suggested that&#x000a0;the presence of at least&#x000a0;2 abnormal findings, including clinical presentation, quantitative sensory testing (QST), and skin biopsy, are the best diagnostic criteria for SFN, other sources have included the inclusion of QSART instead of skin biopsy for diagnosis.<xref ref-type="bibr" rid="article-143426.r14">[14]</xref><xref ref-type="bibr" rid="article-143426.r15">[15]</xref>&#x000a0;While as many as half of cases of SFN are considered idiopathic, it is important to attempt to find the underlying cause to find a possible treatment.<xref ref-type="bibr" rid="article-143426.r16">[16]</xref> Testing&#x000a0;may include the following:</p>
        <p>
<bold>First Tier Studies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Complete blood cell count to evaluate for hematologic abnormalities</p>
          </list-item>
          <list-item>
            <p>Complete metabolic panel to assess for renal or hepatic impairment</p>
          </list-item>
          <list-item>
            <p>Lipid panel to evaluate for hyperlipidemia</p>
          </list-item>
          <list-item>
            <p>Erythrocyte sedimentation rate, C-reactive protein, and antinuclear antibody to evaluate for inflammatory disease</p>
          </list-item>
          <list-item>
            <p>Thyroid-stimulating hormone, free T4, and T3 levels to assess for hypothyroidism</p>
          </list-item>
          <list-item>
            <p>2-hour oral glucose tolerance test and hemoglobin A1C to evaluate for diabetes and impaired glucose tolerance</p>
          </list-item>
          <list-item>
            <p>Extractable nuclear antigen testing for Sj&#x000f6;gren syndrome A and B antibodies</p>
          </list-item>
          <list-item>
            <p>Vitamin B12, methylmalonic acid, and homocysteine levels to assess for vitamin B12 deficiency</p>
          </list-item>
          <list-item>
            <p>Tissue transglutaminase and antigliadin antibodies to evaluate for Celiac disease</p>
          </list-item>
          <list-item>
            <p>Human immunodeficiency virus (HIV) and hepatitis C virus antibodies to evaluate for HIV and hepatitis&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Second Tier Studies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Angiotensin-converting enzyme to evaluate for sarcoidosis</p>
          </list-item>
          <list-item>
            <p>Thiamine (vitamin B1) to evaluate for vitamin B1 deficiency</p>
          </list-item>
          <list-item>
            <p>Pyridoxine (vitamin B6) to assess for vitamin B6 deficiency</p>
          </list-item>
          <list-item>
            <p>Copper level to evaluate for copper deficiency</p>
          </list-item>
          <list-item>
            <p>Serum and urine monoclonal protein analysis, nerve biopsy, and fat pad analysis to evaluate for systemic amyloidosis</p>
          </list-item>
          <list-item>
            <p>Paraneoplastic autoantibody panel to evaluate for paraneoplastic disease</p>
          </list-item>
          <list-item>
            <p>Ganglionic acetylcholine receptor antibodies to evaluate for autoimmune autonomic ganglionopathy</p>
          </list-item>
        </list>
        <p>
<bold>Genetic Studies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>SCN9A and SCN10A genes to evaluate for hereditary&#x000a0;SFN</p>
          </list-item>
          <list-item>
            <p>GLA gene to evaluate for Fabry disease</p>
          </list-item>
          <list-item>
            <p>Transthyretin gene to evaluate for familial amyloidosis</p>
          </list-item>
          <list-item>
            <p>ABCA1 gene to evaluate for Tangier disease&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-143426.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The management of SFN should involve treatment of the underlying etiology in patients with an identified cause of neuropathy. Diabetes should be managed with glycemic and lipid-lowering agents and lifestyle modifications focusing specifically on nutrition and exercise. Since walking and running may be difficult for SFN patients due to pain, alternative exercises may be pursued, including aqua therapy, swimming, and stationary cycling. In cases of Vitamin B12 deficiency, parenteral rather than oral supplementation is often recommended as the deficiency is often due to reduced absorption rather than low dietary intake. A suggested regimen may consist of intramuscular or subcutaneous methylcobalamin 1,000&#x000a0;&#x003bc;g injection given once daily for&#x000a0;1 week, once weekly for&#x000a0;1 month, and a monthly maintenance dose for the next 6 to 12 months. As per anecdotal case reports, painful SFN and dysautonomia secondary to&#x000a0;Sj&#x000f6;gren syndrome have been treated successfully with corticosteroids, intravenous immune globulin (IVIG), and other immunosuppressants.<xref ref-type="bibr" rid="article-143426.r17">[17]</xref>&#x000a0;</p>
        <p>SFN associated with sarcoidosis may also be treated with IVIG, infliximab, and combination therapy.<xref ref-type="bibr" rid="article-143426.r18">[18]</xref>&#x000a0;Patients with SFN secondary to celiac disease may find relief&#x000a0;from SFN symptoms with a gluten-free diet.&#x000a0;Pain management is important in the treatment of SFN, as neuropathic pain may be debilitating and cause a decrease in function and depression. Pain secondary to SFN is often best managed with a multidisciplinary team, which may involve a primary care physician, a pain management specialist, a neurologist, and a psychiatrist. Medications used in the treatment of SFN include anticonvulsants, antidepressants, topical anesthetics, narcotics, non-narcotic analgesics, and antiarrhythmics. In contrast, nonpharmacologic treatments such as heat, ice, massage of painful areas, and transcutaneous electrical nerve stimulation (TENS) may also be used.<xref ref-type="bibr" rid="article-143426.r19">[19]</xref>&#x000a0;</p>
        <p>First-line medications are the anticonvulsant medications gabapentin and pregabalin, the tricyclic antidepressants amitriptyline and nortriptyline, the semisynthetic opioid analgesic tramadol, and a 5% topical lidocaine patch. These medications may be used either alone or in combination. Nonsteroidal anti-inflammatory medications and selective serotonin reuptake inhibitors may also be used; however, they are often less effective than the previously mentioned drugs. The voltage-gated sodium channel blocker Mexiletine typically used as an antiarrhythmic medication, may help with refractory pain related to sodium channel dysfunction.<xref ref-type="bibr" rid="article-143426.r20">[20]</xref>&#x000a0; Opioid medications should be reserved only for refractory cases; given the potential for addiction, however, they may sometimes be necessary for patients with debilitating pain who do not respond to other medications. Regimens that combine medications with different mechanisms may be most effective. A study that evaluated a treatment regimen combining gabapentin and nortriptyline found such treatment to be more effective than either drug alone in treating neuropathic pain.<xref ref-type="bibr" rid="article-143426.r21">[21]</xref>&#x000a0;</p>
        <p>Treatment with inhaled cannabis was found to reduce pain in patients with diabetic neuropathy and HIV; however, side effects, including somnolence, euphoria, and cognitive impairment, were noted.<xref ref-type="bibr" rid="article-143426.r22">[22]</xref>&#x000a0;Holistic therapies such as yoga, tai chi, and meditation may help with pain, quality of life, and balance in patients with neuropathy.<xref ref-type="bibr" rid="article-143426.r23">[23]</xref>&#x000a0;In many cases, neuromodulation has proven effective in treating the painful symptoms of SFN. Treatments include traditional dorsal column stimulation, dorsal horn stimulation, and dorsal root ganglion stimulation.<xref ref-type="bibr" rid="article-143426.r24">[24]</xref><xref ref-type="bibr" rid="article-143426.r25">[25]</xref><xref ref-type="bibr" rid="article-143426.r26">[26]</xref></p>
      </sec>
      <sec id="article-143426.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>As previously mentioned, it is imperative to differentiate small fiber from large fiber neuropathy. Findings such as weakness, reduced proprioception, and absent deep tendon reflexes indicate large fiber (A<italic toggle="yes">&#x003b1;</italic>- and A&#x003b2;) involvement and may differentiate large fiber neuropathy from SFN. EMG and nerve conduction studies are also helpful in this differentiation, as these studies are normal with small fiber involvement and abnormal with large fiber involvement. EMG may also differentiate from lumbar radiculopathy, which may present with lower extremity burning and numbness. Differentiation between these conditions is imperative for implementing a proper treatment regimen, as management of these conditions varies.</p>
      </sec>
      <sec id="article-143426.s10" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <p>
<bold>&#x000a0;&#x000a0;Table 2&#x000a0;<xref ref-type="bibr" rid="article-143426.r2">[2]</xref></bold>
</p>
        <table-wrap id="article-143426.table1" position="float" orientation="portrait">
          <table style="width: 565.71875px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 172px;" rowspan="1" colspan="1">Treatment (medication Category)</td>
                <td style="width: 90px;" rowspan="1" colspan="1">Dosage (per day)</td>
                <td style="width: 229.71875px;" rowspan="1" colspan="1">Common Adverse Effects</td>
              </tr>
              <tr>
                <td style="width: 172px;" rowspan="1" colspan="1">Gabapentin (Anticonvulsant)</td>
                <td style="width: 90px;" rowspan="1" colspan="1">300-3,600 mg</td>
                <td style="width: 229.71875px;" rowspan="1" colspan="1">sedation, dizziness, weight gain, peripheral edema</td>
              </tr>
              <tr>
                <td style="width: 172px;" rowspan="1" colspan="1">Pregabalin (Anticonvulsant)</td>
                <td style="width: 90px;" rowspan="1" colspan="1">150-600 mg</td>
                <td style="width: 229.71875px;" rowspan="1" colspan="1">sedation, dizziness, weight gain, peripheral edema</td>
              </tr>
              <tr>
                <td style="width: 172px;" rowspan="1" colspan="1">Topiramate (Anticonvulsant)</td>
                <td style="width: 90px;" rowspan="1" colspan="1">25-400 mg</td>
                <td style="width: 229.71875px;" rowspan="1" colspan="1">weight loss, cognitive slowing, sedation, renal stones, paresthesias, glaucoma, depression with suicidal ideation</td>
              </tr>
              <tr>
                <td style="width: 172px;" rowspan="1" colspan="1">Amitriptyline (Antidepressant)</td>
                <td style="width: 90px;" rowspan="1" colspan="1">20-100 mg</td>
                <td style="width: 229.71875px;" rowspan="1" colspan="1">sedation, anticholinergic effects, weight gain,&#x000a0;arrhythmia, sexual dysfunction</td>
              </tr>
              <tr>
                <td style="width: 172px;" rowspan="1" colspan="1">Nortriptyline&#x000a0;(Antidepressant)</td>
                <td style="width: 90px;" rowspan="1" colspan="1">20-100 mg</td>
                <td style="width: 229.71875px;" rowspan="1" colspan="1">sedation, anticholinergic effects, weight gain,&#x000a0;arrhythmia, sexual dysfunction</td>
              </tr>
              <tr>
                <td style="width: 172px;" rowspan="1" colspan="1">Lidocaine 5% patch (topical anesthetic)</td>
                <td style="width: 90px;" rowspan="1" colspan="1">3 patches for 12 hours</td>
                <td style="width: 229.71875px;" rowspan="1" colspan="1">local edema, erythema, burning</td>
              </tr>
              <tr>
                <td style="width: 172px;" rowspan="1" colspan="1">Capsaicin 0.75% (topical anesthetic)</td>
                <td style="width: 90px;" rowspan="1" colspan="1">apply up to 4 times per day</td>
                <td style="width: 229.71875px;" rowspan="1" colspan="1">burning</td>
              </tr>
              <tr>
                <td style="width: 172px;" rowspan="1" colspan="1">Tramadol (semisynthetic opioid analgesic)</td>
                <td style="width: 90px;" rowspan="1" colspan="1">50-400 mg</td>
                <td style="width: 229.71875px;" rowspan="1" colspan="1">sedation, seizures, dizziness, constipation, nausea</td>
              </tr>
              <tr>
                <td style="width: 172px;" rowspan="1" colspan="1">Mexiletine (voltage-gated sodium channel blocker)</td>
                <td style="width: 90px;" rowspan="1" colspan="1">200-600 mg</td>
                <td style="width: 229.71875px;" rowspan="1" colspan="1">nausea, vomiting, dry mouth, abdominal pain</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-143426.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Most patients with SFN experience a slowly progressive course, with a clinical plateau reached following years of symptom development. One study showed only 13% of 124 patients with SFN had developed signs of&#x000a0;large-fiber involvement over 2 years.<xref ref-type="bibr" rid="article-143426.r27">[27]</xref>&#x000a0;This same study found that none of the patients developed Charcot joints, weakness, sensory ataxia, or foot ulcers, which are symptoms typically seen in patients with chronic or severe large fiber neuropathy. It additionally found that over half of the patients either improved or remained stable over the&#x000a0;2 years. Further studies would be useful in evaluating symptomatic progression over a&#x000a0;period longer than&#x000a0;2 years.&#x000a0;</p>
      </sec>
      <sec id="article-143426.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The risk for complications in patients with SFN often varies based on the underlying etiology. Proper treatment should be sought and implemented to prevent disease progression related to underlying medical conditions. The pain brought about by SFN may also cause dysfunction and inactivity in patients. For this reason, proper pain control is imperative for the continuation of physical activity to prevent complications of inactivity, including weight gain and depression.</p>
      </sec>
      <sec id="article-143426.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients diagnosed with SFN should be educated regarding strategies to lessen the burden of their neuropathic pain and the proper management of any possible underlying condition.</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients with diabetes should be educated regarding diet, exercise, and insulin (if necessary). Regular outpatient follow-up should be arranged with primary care, podiatry, ophthalmology, endocrinology, and cardiology.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patients with SFN secondary to alcohol should be provided with resources for alcohol abstinence.</p>
          </list-item>
          <list-item>
            <p>Patients with nutritional deficiencies such as vitamin B12 should be educated on proper supplementation.</p>
          </list-item>
          <list-item>
            <p>Patients with SFN in infectious etiologies such as HIV, Lyme, and hepatitis C should be educated regarding proper antiviral treatment for their underlying infection.</p>
          </list-item>
          <list-item>
            <p>Patients with immune-mediated and hereditary etiologies of their SFN should be educated regarding treatment strategies and other possible complications related to their underlying condition.</p>
          </list-item>
        </list>
        <p>In addition to education regarding the proper management of underlying conditions related to SFN, emphasis should be placed on continuing physical activity.</p>
      </sec>
      <sec id="article-143426.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>A strong clinician-patient relationship is imperative for improving healthcare outcomes. Good communication amongst an interprofessional team, which may include a neurologist, pain medicine physician, physiatrist, primary care clinician, dietician, and nurse, is key. SFN may cause&#x000a0;debilitating pain without proper management, often leading to deconditioning and depression. Cause-specific treatment, pain control, and lifestyle modification are key elements in the team approach to managing SFN.</p>
      </sec>
      <sec id="article-143426.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=143426&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=143426">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/small-fiber-neuropathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=143426">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/143426/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=143426">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-143426.s16">
        <title>References</title>
        <ref id="article-143426.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tavee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Small fiber neuropathy: A burning problem.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2009</year>
            <month>May</month>
            <volume>76</volume>
            <issue>5</issue>
            <fpage>297</fpage>
            <page-range>297-305</page-range>
            <pub-id pub-id-type="pmid">19414545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tavee</surname>
                <given-names>JO</given-names>
              </name>
            </person-group>
            <article-title>Office approach to small fiber neuropathy.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>85</volume>
            <issue>10</issue>
            <fpage>801</fpage>
            <page-range>801-812</page-range>
            <pub-id pub-id-type="pmid">30289758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devigili</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cazzato</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lauria</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Clinical diagnosis and management of small fiber neuropathy: an update on best practice.</article-title>
            <source>Expert Rev Neurother</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>20</volume>
            <issue>9</issue>
            <fpage>967</fpage>
            <page-range>967-980</page-range>
            <pub-id pub-id-type="pmid">32654574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hovaguimian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gibbons</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of pain in small-fiber neuropathy.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>193</fpage>
            <page-range>193-200</page-range>
            <pub-id pub-id-type="pmid">21286866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacomis</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Small-fiber neuropathy.</article-title>
            <source>Muscle Nerve</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>173</fpage>
            <page-range>173-88</page-range>
            <pub-id pub-id-type="pmid">12210380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Themistocleous</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Ramirez</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Shillo</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Selvarajah</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Orengo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tesfaye</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rice</surname>
                <given-names>ASC</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>DLH</given-names>
              </name>
            </person-group>
            <article-title>The Pain in Neuropathy Study (PiNS): a cross-sectional observational study determining the somatosensory phenotype of painful and painless diabetic neuropathy.</article-title>
            <source>Pain</source>
            <year>2016</year>
            <month>May</month>
            <volume>157</volume>
            <issue>5</issue>
            <fpage>1132</fpage>
            <page-range>1132-1145</page-range>
            <pub-id pub-id-type="pmid">27088890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raasing</surname>
                <given-names>LRM</given-names>
              </name>
              <name>
                <surname>Vogels</surname>
                <given-names>OJM</given-names>
              </name>
              <name>
                <surname>Veltkamp</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Swol</surname>
                <given-names>CFP</given-names>
              </name>
              <name>
                <surname>Grutters</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Current View of Diagnosing Small Fiber Neuropathy.</article-title>
            <source>J Neuromuscul Dis</source>
            <year>2021</year>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>185</fpage>
            <page-range>185-207</page-range>
            <pub-id pub-id-type="pmid">33337383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peters</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bakkers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Merkies</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Hoeijmakers</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>van Raak</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Faber</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Incidence and prevalence of small-fiber neuropathy: a survey in the Netherlands.</article-title>
            <source>Neurology</source>
            <year>2013</year>
            <month>Oct</month>
            <day>08</day>
            <volume>81</volume>
            <issue>15</issue>
            <fpage>1356</fpage>
            <page-range>1356-60</page-range>
            <pub-id pub-id-type="pmid">23997150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vallbo</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Hagbarth</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Torebj&#x000f6;rk</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Wallin</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>Somatosensory, proprioceptive, and sympathetic activity in human peripheral nerves.</article-title>
            <source>Physiol Rev</source>
            <year>1979</year>
            <month>Oct</month>
            <volume>59</volume>
            <issue>4</issue>
            <fpage>919</fpage>
            <page-range>919-57</page-range>
            <pub-id pub-id-type="pmid">227005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madsen</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Finnerup</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Baumg&#x000e4;rtner</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Assessment of small fibers using evoked potentials.</article-title>
            <source>Scand J Pain</source>
            <year>2014</year>
            <month>Apr</month>
            <day>01</day>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>111</fpage>
            <page-range>111-118</page-range>
            <pub-id pub-id-type="pmid">29913679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Callaghan</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Distal Symmetric Polyneuropathy: A Review.</article-title>
            <source>JAMA</source>
            <year>2015</year>
            <month>Nov</month>
            <day>24</day>
            <volume>314</volume>
            <issue>20</issue>
            <fpage>2172</fpage>
            <page-range>2172-81</page-range>
            <pub-id pub-id-type="pmid">26599185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herrmann</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Hauer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cornblath</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies.</article-title>
            <source>Neurology</source>
            <year>1999</year>
            <month>Nov</month>
            <day>10</day>
            <volume>53</volume>
            <issue>8</issue>
            <fpage>1634</fpage>
            <page-range>1634-40</page-range>
            <pub-id pub-id-type="pmid">10563605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stewart</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Low</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Fealey</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Distal small fiber neuropathy: results of tests of sweating and autonomic cardiovascular reflexes.</article-title>
            <source>Muscle Nerve</source>
            <year>1992</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>661</fpage>
            <page-range>661-5</page-range>
            <pub-id pub-id-type="pmid">1324425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blackmore</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Siddiqi</surname>
                <given-names>ZA</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic Criteria for Small Fiber Neuropathy.</article-title>
            <source>J Clin Neuromuscul Dis</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>125</fpage>
            <page-range>125-131</page-range>
            <pub-id pub-id-type="pmid">28221302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lauria</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Johansson</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Leger</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mellgren</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Nolano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Merkies</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Polydefkis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Sommer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Valls-Sol&#x000e9;</surname>
                <given-names>J</given-names>
              </name>
              <collab>European Federation of Neurological Societies</collab>
              <collab>Peripheral Nerve Society</collab>
            </person-group>
            <article-title>European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.</article-title>
            <source>Eur J Neurol</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>17</volume>
            <issue>7</issue>
            <fpage>903</fpage>
            <page-range>903-12, e44-9</page-range>
            <pub-id pub-id-type="pmid">20642627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Greef</surname>
                <given-names>BTA</given-names>
              </name>
              <name>
                <surname>Hoeijmakers</surname>
                <given-names>JGJ</given-names>
              </name>
              <name>
                <surname>Gorissen-Brouwers</surname>
                <given-names>CML</given-names>
              </name>
              <name>
                <surname>Geerts</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Faber</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Merkies</surname>
                <given-names>ISJ</given-names>
              </name>
            </person-group>
            <article-title>Associated conditions in small fiber neuropathy - a large cohort study and review of the literature.</article-title>
            <source>Eur J Neurol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>348</fpage>
            <page-range>348-355</page-range>
            <pub-id pub-id-type="pmid">29112785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berkowitz</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Samuels</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>The neurology of Sjogren's syndrome and the rheumatology of peripheral neuropathy and myelitis.</article-title>
            <source>Pract Neurol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-22</page-range>
            <pub-id pub-id-type="pmid">24307005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tavee</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Karwa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Parambil</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Culver</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Sarcoidosis-associated small fiber neuropathy in a large cohort: Clinical aspects and response to IVIG and anti-TNF alpha treatment.</article-title>
            <source>Respir Med</source>
            <year>2017</year>
            <month>May</month>
            <volume>126</volume>
            <fpage>135</fpage>
            <page-range>135-138</page-range>
            <pub-id pub-id-type="pmid">28318820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lamer</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Rho</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Sitzman</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Ghazi</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Contemporary management of neuropathic pain for the primary care physician.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>79</volume>
            <issue>12</issue>
            <fpage>1533</fpage>
            <page-range>1533-45</page-range>
            <pub-id pub-id-type="pmid">15595338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bril</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>England</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Backonja</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Del Toro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Iverson</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Perkins</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Zochodne</surname>
                <given-names>D</given-names>
              </name>
              <collab>American Academy of Neurology</collab>
              <collab>American Association of Neuromuscular and Electrodiagnostic Medicine</collab>
              <collab>American Academy of Physical Medicine and Rehabilitation</collab>
            </person-group>
            <article-title>Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.</article-title>
            <source>PM R</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>345</fpage>
            <page-range>345-52, 352.e1-21</page-range>
            <pub-id pub-id-type="pmid">21497321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilron</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Holden</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Houlden</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial.</article-title>
            <source>Lancet</source>
            <year>2009</year>
            <month>Oct</month>
            <day>10</day>
            <volume>374</volume>
            <issue>9697</issue>
            <fpage>1252</fpage>
            <page-range>1252-61</page-range>
            <pub-id pub-id-type="pmid">19796802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallace</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Marcotte</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Umlauf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gouaux</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy.</article-title>
            <source>J Pain</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>16</volume>
            <issue>7</issue>
            <fpage>616</fpage>
            <page-range>616-27</page-range>
            <pub-id pub-id-type="pmid">25843054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tavee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rensel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Planchon</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Effects of meditation on pain and quality of life in multiple sclerosis and peripheral neuropathy: a pilot study.</article-title>
            <source>Int J MS Care</source>
            <year>2011</year>
            <season>Winter</season>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>163</fpage>
            <page-range>163-8</page-range>
            <pub-id pub-id-type="pmid">24453721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eckmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Papanastassiou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Awad</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A Unique Case for Spinal Cord Stimulation: Successful Treatment of Small Fiber Neuropathy Pain Using Multiple Spinal Cord Stimulators.</article-title>
            <source>Case Rep Med</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>6969285</fpage>
            <pub-id pub-id-type="pmid">28791051</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maino</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Koetsier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kaelin-Lang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gobbi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Efficacious Dorsal Root Ganglion Stimulation for Painful Small Fiber Neuropathy: A Case Report.</article-title>
            <source>Pain Physician</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>E459</fpage>
            <page-range>E459-E463</page-range>
            <pub-id pub-id-type="pmid">28339448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayek</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Veizi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hanes</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Treatment-Limiting Complications of Percutaneous Spinal Cord Stimulator Implants: A Review of Eight Years of Experience From an Academic Center Database.</article-title>
            <source>Neuromodulation</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>7</issue>
            <fpage>603</fpage>
            <page-range>603-8; discussion 608-9</page-range>
            <pub-id pub-id-type="pmid">26053499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143426.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khoshnoodi</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Truelove</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Burakgazi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hoke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mammen</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Polydefkis</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Longitudinal Assessment of Small Fiber Neuropathy: Evidence of a Non-Length-Dependent Distal Axonopathy.</article-title>
            <source>JAMA Neurol</source>
            <year>2016</year>
            <month>Jun</month>
            <day>01</day>
            <volume>73</volume>
            <issue>6</issue>
            <fpage>684</fpage>
            <page-range>684-90</page-range>
            <pub-id pub-id-type="pmid">27065313</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
